Adipokiny i serdechno-sosudistye zabolevaniya


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article provides an overview of research on the role of adipokines (leptin, adiponectin, resistin) - proteins secreted by adipose tissue, which are associated with weight gain, insulin resistance, atherosclerosis and the development of cardiovascular diseases.

Full Text

Restricted Access

References

  1. Аметов А.С. Избранные лекции по эндокринологии. М., 2009. 496.
  2. Вербовая Н.И., Капралова И.Ю., Вербовой А.Ф. Содержание остеопротегерина и адипокинов при гипотиреозе у женщин. Врач. 2014;8:66-8.
  3. Вербовой А.Ф. Ожирение, манифестировавшее в пубертатный период. Самара, 2012;100.
  4. Вербовой А.Ф., Ворожцова Е.И., Орлова Т.Н. Метаболические показатели у мужчин с сахарным диабетом 2 типа и ИБС. Фарматека. 2012;9:60-4.
  5. Вербовой А.Ф., Митрошина Е.В., Долгих Ю.А. Адипокины, инсулинорезистентность и активность симпато-адреналовой системы у юношей с ожирением, манифестировавшим в пубертатный период. Ожирение и метаболизм. 2012;2:41-4.
  6. Вербовой А.Ф., Митрошина Е.В., Долгих Ю.А. Состояние сердца у юношей с ожирением, манифестировавшим в пубертатный период. Врач, 2012;5:27-30.
  7. Вербовой А.Ф., Решетова О.Н. Грелин и гормонально-метаболические показатели у юношей с ожирением и избыточной массой тела. Проблемы эндокринологии. 2009;2:23-6.
  8. Вербовой А.Ф., Скудаева Е.С., Пашенцева А.В. Уровни резистина, адипонектина и инсулинорезистентности у пациентов с разной степенью нарушений углеводного обмена. Ожирение и метаболизм. 2011;3:57-60.
  9. Волов Н.А., Адамов П.Б., Лебедева А.Ю., Туренко О.И., Софрина С.Л. Лептин - новый фактор риска сердечно-сосудистых заболеваний. Терапевт. 2011;8:50-4.
  10. Долгих Ю.А. Роль лептина и резистина в развитии инсулинорезистентности у юношей с ожирением, манифестировавшим в пубертатный период. Дисс. канд. мед. наук. Самара, 2013;23.
  11. Митрошина Е.В. Клинико-лабораторные особенности ожирения, манифестировавшего в пубертатный период у юношей и мужчин. Дисс. канд. мед. наук. Самара. 2011. 24 с.
  12. Метаболический синдром / Под ред. гл. -корр. РАМН Г.Е. Ройтберга. М., 2007. 224.
  13. Морковских Н.В. Маркеры эндокринной системы и воспаления как прогностические факторы риска сосудистых осложнений при сахарном диабете 2 типа. Дисс. канд. мед. наук. Самара, 2010. 142.
  14. Пашенцева А.В. Роль лептина и резистина в развитии инсулинорезистентности у больных сахарным диабетом 2 типа. Дисс. канд. мед. наук. Самара. 2012;23.
  15. Решетова О.Н. Грелин и гормональнометаболические показатели у юношей с пубертатно-юношеским диспитуитаризмом. Дисс. канд. мед. наук. Самара, 2009;136.
  16. Скудаева Е.С., Пашенцева А.В., Вербовой А.Ф. Уровни резистина, адипонектина и инсулинорезистентности у пациентов с разной степенью нарушений углеводного обмена. Ожирение и метаболизм. 2011;3:57-60.
  17. Соломонова Е., Вербовой А. Жировая ткань и ад ипокины. LAP LAMBERT A cadem ic Publi-sh ing -Saarbriicken, 2012. 115 p.
  18. Фомина И.А. Взаимосвязь лептина и метаболических показателей при пубертатноюношеском диспитуитаризме у юношей. Дисс. канд. мед. наук. Самара, 2009. 22 c.
  19. Черныш О.В., Мохорт Т.В. Вариабельность базальных уровней грелина с различными нарушениями углеводного обмена при метаболическом синдроме. Ожирение и метаболизм. 2007;1(10):30-4.
  20. Antoniades C., Antonopoulos A.S., Tousoulis D., et al. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10(3):269-79.
  21. Kumada M., Kihara S., Sumitsuji S., et al., Osaka CAD Study Group. Association of hypoadipo-nectinemia with coronary artery disease in men. Coronary artery disease. Artrioscler. Thromb. Vasc. Biol. 2003;1,23(1):85-9.
  22. Boyraz M., Cekmez F., Karaoglu A., et al. Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children. Biomark Med. 2013;7(3):423-28.
  23. Chu S., Ding W., Li K., Pang Y., Tang C. Plasma resistin associated with myocardium unjury in patients with acute coronary syndrome. Circulation. 2008;72 (8):1249-53.
  24. Cooke J.R., Oka R.K. Does leptin cause vascular deasese? Circulation. 2002; 106:1904.
  25. Corsonello A, Malara A., Intile R., Corica F. Leptin enhances adenosine diphosphate - induces platelet aggregation in healthy subjects. Obes. Res. 2002;10(4):306.
  26. Costacou T., Zgibor J.C., Evans R.W., et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2005;48(1):41-8.
  27. Dekker J.M., Funahashi T., Nijpels G. et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J. Clin. Endocrinol. Metab. 2008;93(4):1489-96.
  28. Espinola-Klein C., Gori T., Blankenberg S., Munzel T. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Frontiers in Bioscience. 2011;16(5):1663- 74.
  29. Fortuno A, Rodriguez A., Gomez-Ambrosi J., et al. Leptin inhibits angiotensin II - induced intracellular calcium increase and vasoconstriction in the rat aorta. Endocrinology. 2002;143(9):3555-60.
  30. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999 Apr., 48 (4): 903-5.
  31. Frystyk J., Berne C., Berglund L. et al. Serum adi-ponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J. Clin. Endocrinol. Metab. 2007; 92 (2): 571-76.
  32. Hercule H.C., Schunck W.H., Gross V., et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler. Tromb.-Vasc. Biol. 2009;29(1):54-60.
  33. Hopking T.A., Ouchi N., Shibata R., Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res.2007. 74(1): 11-8.
  34. Hotta K., Funahashi T., Aruta Y., et al. Plasma concentrations of a novel adipose-specific protein, adiponectin in type 2 diabetic agents. Arterioscler. Thromb. Vasc. Biol. 2000; 20:1595-99.
  35. Hu W.L., Qiao S.B., Hou Q., Yuan J.S. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circulation. 2008;72 (8): 1249-53.
  36. Hu W.L., Qiao S.B., Hou Q., Yuan J.S. Plasma resistin associated with unstable angina. Chinese Medical J. 2007;120(10):871-75.
  37. Hung W.C., Wang C.P., Lu L.F., et al. Circulating adiponectin level is associated with major adverse cardiovascular events in type 2 diabetic patients with coronary artery disease. Endocr. J. 2010;5 7(9):793-802.
  38. Jaleel A., Aheed B., Jaleel S., et al. Association of adipokines with obesity in children and adolescents. Biomark. Med. 2013;7(5):731-35.
  39. Jamaluddin M.S., Weakley S.M., Yao Q., et al. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br. J. Pharmacol. 2012;165(3):622-32.
  40. Joseph N.A., Greenberg A.S. Adipocitokines and insulin resistance. J. Clin. Endocrinol. Metab. 2004;89(2):447-60.
  41. Jung H.S., Park K.H., Cho Y.M., et al. Resistin is secreted from macropages in atheromas and promotes atherosclerosis. Cardiovasc. Res.2006;69( 1 ):76-85.
  42. Karaduman M., Oktenli C. Musabak U., et al. Leptin, soluble interleikin-6 receptor, C - reactive protein and soluble vascular cell adhesion molecule-1 levels in human coronary atheroscloretic plague. Clin. Exper. Immunol. 2006;143(3):452-57.
  43. Kizer J.R., Arnold A.M., Benkeser D., et al. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care. 2012;35(2):415-23.
  44. Koenig W., Khuseyinova N., Baumert J., et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J. Am. Coll. Cardiol. 2006; 48(7):1369-77.
  45. Lembo G., Vecchione C., Fratta L., et al. Leptin induces direct vasodilatation through distinct endothelial mechanisms. Diabetes. 2000; 49(2):293-97.
  46. Liao Y., Takashima S., Maeda N., et al. Exacerbation of Heart failure in adiponectin - deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 2005;67:705-13.
  47. Lindberg S., Jensen J.S., Bjerre M., et al. Adiponectin, type 2 diabetes and cardiovascular risk. Eur. J. Prev. Cardiol. 2013; http://www.ncbi.nlm.nih.gov/pub med/?term=L indberg+S%2C+Jensen +JS%2C+Bje rre+M+et+al.+Adiponectin%2C+type+2+diabet es+and+cardiovascular+risk (25 Nov 2013)
  48. Lindberg S., Mogelvang R., Pedersen S.H., et al. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am. J. Cardiol. 2013;111(8): 1139-45.
  49. Maingrette F., Renier G. Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. Diabetes. 2003;52(8):2121-28.
  50. Matsuda M., Shimomura I., Sata M., еt al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem. 2002;2 77(40):3 7487-491.
  51. Melone M., Wilsie L., Palyha O., et al. Discovery of a new role of human resistin hepotocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subutilisin/Kexin type 9. J. Am. College Cardiol. 2012;59(19):1697-705.
  52. Motobayashi Y., Izawa-Ishizawa Y., Ishizawa K., et al. Adiponectin inhibits insulin - like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells. Hypertens. Res, 2009;32(3): 188-93.
  53. Nakata M., Yada T., Soejima N; Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes. 1999;48 (2):426-29.
  54. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14):1730-37.
  55. Plutzky J. Inflammatory in atherosclerosis and acute coronary syndromes. Am. J. Cardiol. 2001 ;88(Suppl.): 10-5.
  56. Poykkos M., Kellokoskv E., Horkkos S., et al. Low plasma ghrelin is associated with insulin resistance, hypertension and prevalence of type 2 diabetes. Diabetes. 2003;52(10):2546-53.
  57. Quehenberger P., Exner M., Sunder - Plasmann R., et. Leptin incluces endothelin-1 in endothelial cell in vitro. Circulation Res. 2002;90(6):711-18.
  58. Rothenbacher D., Brenner H., Marz W., et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur. Heart. J. 2005;26( 16): 1640-46.
  59. Rus H.G., Xlaicu R., Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall Atherosclerosis. 1996;127(2):262-71.
  60. Shankar A., Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension. 2010;56(4):623-28.
  61. Shibata R., Ouchi N., Ito M., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 2004;10:1384-89.
  62. Sierra-Johnson J., et al. Relation of Increased Leptin Concentrations to History of Myocardial Infarction and Stroke in the United State Population. Am. J. Cardiol. 2007;100:234-39.
  63. Singer J.R., Palmas W., Teresi J., et al. Adiponectin and all-cause mortality in elderly people with type 2 diabetes. Diabetes Care. 2012;35(9):1858-63.
  64. Singh P., Hoffmann M., Wolk R., et al. Leptin induces C-reactive protein expression in vascular endothelial protein expression in vascular endothelial cells. Arterioscler., Thromb. Vasc. Biol. 2007;27(9):302-7.
  65. Steinle N.I., Pollin T.I., O'Connell J.R., Mitchell B.D., Shuldiner A.R. Variants in the ghrelin gene are associated with metabolic syndrome in the old order Amish. J. Clin. Endocrinol. Metab. 2005;90(12):6672-77.
  66. Tao L., Gao E, Jiao X., et al. Adiponectin cardio-protection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007;115(11):1408-16.
  67. von Eynatten M., Hamann A., Twardella D., et al. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin. Chem. 2006;52(5):853-59.
  68. Wang W.L., Chen D.Y., Cao J., et al. High serum resistin level may be an indicator of the severity of coronary disease in acute coronary syndrome. Chin. Med. J. 2007;120(10):871-75.
  69. Wannamethee S.G., Welsh P., Whincup P.H., et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur. J. Cardiovasc. Prevent. Rehabilit. 2011;18(1):65-71.
  70. Wannamethee S.G., Whincup P.H., Lennon L., et al. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch. Intern. Med. 2007;167(14):1510-17.
  71. Yamauchi T., Kamon J., Waki H., et al. Clobular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 2003;278(4):2461-68. Epub 2002. Nov. 12.
  72. Zwaka T.P., Homback V., Torzewski J. C-protein -mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103(9):1194-97.
  73. Zeidan A., Purdham D.M., Rajapurohitam V., et al. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II - and endothelin-1 - dependent mechanisms and mediates stretch -incluced hypertrophy. J. Pharmacol. Exper. Therap. 2005;315(3): 1075-85.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies